{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling within the tumor microenvironment.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "The mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Interferon-associated antigen processing and presentation pathways increase after mRNA vaccination, leading to a broader peptide repertoire on MHC-I molecules.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%",
          "line_ref": "L29"
        },
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        }
      ],
      "caveat": "The expansion of MHC-I-presented peptides was primarily demonstrated in mouse models; human translational evidence is indirect."
    },
    {
      "claim_id": "C03",
      "claim": "PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with immune checkpoint blockade.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x",
          "line_ref": "L32"
        },
        {
          "quote": "Checkpoint axis became more targetable",
          "line_ref": "L32"
        }
      ],
      "caveat": "While PD-L1 expression increased, the direct clinical benefit in combination therapy requires prospective validation."
    },
    {
      "claim_id": "C04",
      "claim": "The combination of intratumoral mRNA vaccination with anti-PD-L1 therapy improves tumor control in preclinical mouse models.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice",
          "line_ref": "L46"
        },
        {
          "quote": "Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.",
          "line_ref": "L19"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors due to species differences in immune responses."
    },
    {
      "claim_id": "C05",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival outcomes in metastatic cancer patients receiving immune checkpoint inhibitors.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01",
          "line_ref": "L30"
        },
        {
          "quote": "Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; vaccination timing varied across patients and confounding factors likely exist."
    },
    {
      "claim_id": "C06",
      "claim": "Lipid nanoparticle delivery vehicles lacking mRNA do not reproduce the tumor sensitization effects observed with mRNA-containing vaccines.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        }
      ],
      "caveat": "The control experiments confirmed that mRNA content, rather than just the delivery vehicle, is responsible for the observed biological effects."
    }
  ]
}